化疗相关性白细胞减少等因素对小细胞肺癌生存期的影响

目的 探讨影响小细胞肺癌（small cell lung cancer,SCLC）患者生存期的因素。方法 回顾性研究123例SCLC患者的临床资料，利用SPSS15.0统计软件Cox回归模型分析性别、年龄、吸烟、合并症、临床分期、ECOG评分、治疗方法、CEA、化疗相关性白细胞减少（chemotherapy induced leucopenia,CIL ）9个预后因素对生存期的影响。结果随访1～52月，死亡103例。6月、1年、2年、3年、4年存活率分别为70.7%、34.1%、8.94%、2.4%、0.8%，中位生存期11月95%CI(9.328, 12.627)]。Cox回归多因素分析显示，影响预后的独立因素是：ECOG评分（P=0.000）、化疗联合放疗（P=0.000）、临床分期（P=0.024）、CIL(P=0.013)。结论临床分期早、ECOG评分低、接受化疗联合放疗且出现CIL的SCLC患者生存期长、预后好。

Impact of CIL on Survival of Patients with Small Cell Lung Cancer

Objective The objective of this study is to discuss the independent prognostic factors in the pa-tients of srnallcell lung cancer(SCLC). Methods One hundred and twenty-three patients of SCLC were reviewed. The potential prognostic factors such as: gender, age, smoke, complication, clinical stage,ECOG performance status, treatment, CEA, chemotherapy induced leucopenia (CIL) were analyzed by Cox regression using SPSS 15.0 software. Results After 1 to 52 months follow-up, 103 patients died.The surival rate in 6 month, 1st year, 2nd year, 3rd year and 4th year were 70.7%,34.1%,8.94%,2.4% and 0.8%,respectively. Median survival time(MST) was 11 months95%CI(9.328, 12.627)].Cox regression showed that the independent prognostic factors on the surival time were ECOG perform-ance status (P=0.000), chemoradiotherapy (P=0.000), clinical stage (P=0. 024), and CIL (P=0.013). Conclusion Patients of SCLC, who are in limited clinic stage,with low ECOG performance sta-tus,have been treated with chemoradiotherapy and showed CIL, will prolong the survival time (P< 0.05) and have a better life quality.